Cure Parkinson’s Grant Supports Potential Iron-trapping Treatment

Cure Parkinson’s is supporting AbFero Pharmaceuticals in its work to advance SP-420, a potential disease-modifying therapy for Parkinson’s disease that clears excess iron from the brain. The grant award supports further testing of AbFero’s lead compound in Parkinson’s models with a goal of moving it into clinical trials. SP-420, a next-generation iron…

AbFero Receives Funding to Advance Iron-trapping Parkinson’s Disease Therapy

AbFero Ltd will receive approximately €2 million ($2.41 million) through Eureka Network’s Eurostars program to complete pre-clinical testing of SP-420, a potential disease-modifying therapy for Parkinson’s disease, and to develop other iron-removing compounds. “This grant is an important step forward for AbFero as we test…